Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2012 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor:
Information provided by (Responsible Party):
C.Y. Ponsioen, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier:
NCT01398917
First received: April 25, 2011
Last updated: July 5, 2012
Last verified: July 2012
  Purpose

Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the biliary tract of unknown origin. Around 50% of patients develop during their disease course narrowing of the main bile duct with corresponding increase in symptoms such as itching, jaundice and abdominal pain. These narrowings can be treated by balloon dilatation or temporary insertion of a plastic endoprosthesis. However, it is not known which of these two therapeutic modalities is best. This study aims to compare both techniques in order to determine which is best in terms of postponing recurrence of the narrowing, safety and costs.


Condition Intervention Phase
Primary Sclerosing Cholangitis
Procedure: plastic endoprosthesis
Procedure: balloon dilatation
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter Randomized Trial Comparing Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis

Resource links provided by NLM:


Further study details as provided by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):

Primary Outcome Measures:
  • recurrence-free interval of the primary dominant stricture [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • number of patients with adverse events in both groups [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    adverse events within first 3 months after the intervention


Estimated Enrollment: 100
Study Start Date: May 2011
Estimated Study Completion Date: May 2015
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: short-term stenting
one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
Procedure: plastic endoprosthesis
one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
Other Name: plastic stent
Active Comparator: balloon dilatation
4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
Procedure: balloon dilatation
4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
Other Name: biliary dilatation balloon

Detailed Description:

Rationale:

Primary sclerosing cholangitis is a chronic progressive fibro-obliterative disease of the biliary tree leading to biliary cirrhosis. During its course, dominant strictures occur in approximately 50% of patients. These can be accompanied by lead worsening of symptoms and jaundice and are an indication for endoscopic treatment. The best form of treatment, either balloon dilatation or short-term stent placement, has never been formally investigated.

Objective:

Primary:

To compare the efficacy of single session balloon dilatation versus short-term stent placement in non-advanced PSC patients with regard to re-intervention free recurrence rate at two years.

Secondary:

To compare the short term efficacy of single balloon dilatation versus short-term stenting with regard to improvement of cholestatic symptoms, biochemical cholestasis, and quality of life in non-endstage PSC patients at three months; to compare the safety of single balloon dilatation session versus short-term stenting in non advanced PSC patients during two years.

Study design: This is a multicenter, open-label, randomized intervention study.

Study population:

Non-advanced primary sclerosing cholangitis subjects with progression of cholestatic complaints from the outpatient population of the seven participating centres.

Main study parameters/endpoints:

  1. Difference in re-intervention free survival time between both groups at two years.
  2. Change in semi-quantitative scoring of cholestatic symptoms (pruritus, right upper quadrant pain, fatigue) from baseline at three months.
  3. Change in total bilirubin, alkaline phosphatase, and yGT from baseline at 3 months.
  4. Safety: adverse events, clinical laboratory values, vital signs.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Currently, both interventions belong to standard patient care armamentarium. Burden for the patient exists in slightly more regular follow-up visits for two years (three-monthly instead of every 3-4 months) to their treating centre. ERCP is associated with a low mortality (<0.5 %) and acceptable morbidity (overall 5%). Most dreaded complications are severe post-ERCP pancreatitis (<2%) and suppurative cholangitis (<2%). From the available retrospective literature data the incidence of these complications does not seem to differ between the two treatment modalities. ERCP will only be performed when there is a clearcut clinical indication anyway.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • PSC ascertained with MRCP, ERCP, PTC and/or liver biopsy or
  • PSC highly suspected and to be confirmed with present ERCP
  • Age between 18-75 years
  • Total bilirubin > 3x ULN or rsie in alkaline phosphatase or bilirubin > 50% together with increase in cholestatic complaints

Exclusion Criteria:

  • Prior stenting or balloon-dilatation within last 6 months
  • Clinical signs serious suppurative cholangitis reflected by either fever > 39.0 °C, tachycardia, leukocytosis and elevated CRP, or fever > 38,5 C together with purulent bile found during ERCP.
  • Change of ursodeoxycholic acid therapy shorter than two months ago.
  • Inability to give written informed consent
  • Signs of biliary cirrhosis Child-Pugh B or C
  • Estimated transplant-free survival shorter than 2 years as calculated by a Mayo score < 2
  • Serious suspicion of cholangiocarcinoma, reflected by an imaging study suggestive of metastasis, MRCP with mass lesion with contrast enhancement, rise in CA19.9 of > 63 U/ml with an absolute value > 130 U/ml 14 .
  • Signs of current malignancy other than basocellular skin carcinoma.
  • Inability to give informed consent.
  • Life expectancy < 24 months.
  • Use of antibiotics in previous 4 weeks.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01398917

Contacts
Contact: Cyriel Y Ponsioen, Dr. +31 20 5666012 c.y.ponsioen@amc.nl
Contact: Florien M Toxopeus, Drs. +31 20 5663005 f.m.toxopeus@amc.nl

Locations
Belgium
UZLeuven Recruiting
Leuven, Belgium
Contact: Werner van Steenbergen, Prof    +3216340749    werner.vansteenbergen@uzleuven.be   
Contact: Natalie van den Ende, BsC    +32 16340749    natalie.vandenende@uzleuven.be   
Netherlands
Academic Medical Center Recruiting
Amsterdam, Netherlands, 1100 DE
Contact: Cyriel Ponsioen, MD PhD    +31 20 5666012    c.y.ponsioen@amc.uva.nl   
Contact: Florien Toxopeus, MsC    +31 20 5669111    f.m.toxopeus@amc.uva.nl   
Principal Investigator: Cyriel Ponsioen, MD PhD         
Norway
Rikshospitalet Recruiting
Oslo, Norway, N-0027
Contact: Lars Aabakken, Prof.    +47 23072387    lars.aabakken@medisin.uio.no   
Contact: Vemund Paulsen, MD    +47 23070000    vemund.paulsen@meisin.uio.no   
Principal Investigator: Lars Aabakken, MD PhD         
Sweden
Karolinska Institute Recruiting
Stockholm, Sweden, 141 86
Contact: Annika Bergquist, prof    +46 8 58582465    annika.bergquist@ki.se   
Contact: Urban Arnelo, dr    +46 8 58582465    urban.arnelo@ki.se   
Principal Investigator: Annika Bergquist, MD PhD         
Sponsors and Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Investigators
Principal Investigator: Cyriel Y Ponsioen, dr. Academic Medical Center, Amsterdam, The Netherlands
  More Information

No publications provided

Responsible Party: C.Y. Ponsioen, Principal Investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier: NCT01398917     History of Changes
Other Study ID Numbers: DILSTENT2, NL34454.018.10
Study First Received: April 25, 2011
Last Updated: July 5, 2012
Health Authority: Netherlands: Medical Ethics Review Committee (METC)
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):
psc
dominant stricture

Additional relevant MeSH terms:
Cholangitis
Cholangitis, Sclerosing
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on October 02, 2014